Candida glabrata: a review of its features and resistance

被引:210
作者
Rodrigues, C. F. [1 ]
Silva, S. [1 ]
Henriques, M. [1 ]
机构
[1] Univ Minho, Ctr Biol Engn, IBB Inst Biotechnol & Bioengn, P-4710057 Braga, Portugal
关键词
ANTIFUNGAL DRUG-RESISTANCE; OXIDATIVE STRESS-RESPONSE; INVASIVE CANDIDIASIS; BIOFILM FORMATION; SACCHAROMYCES-CEREVISIAE; FUNGAL PATHOGEN; YEAST PATHOGEN; FLUCONAZOLE SUSCEPTIBILITY; REDUCED SUSCEPTIBILITY; NOSOCOMIAL CANDIDEMIA;
D O I
10.1007/s10096-013-2009-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Candida species belong to the normal microbiota of the oral cavity and gastrointestinal and vaginal tracts, and are responsible for several clinical manifestations, from mucocutaneous overgrowth to bloodstream infections. Once believed to be non-pathogenic, Candida glabrata was rapidly blamable for many human diseases. Year after year, these pathological circumstances are more recurrent and problematic to treat, especially when patients reveal any level of immunosuppression. These difficulties arise from the capacity of C. glabrata to form biofilms and also from its high resistance to traditional antifungal therapies. Thus, this review intends to present an excerpt of the biology, epidemiology, and pathology of C. glabrata, and detail an approach to its resistance mechanisms based on studies carried out up to the present.
引用
收藏
页码:673 / 688
页数:16
相关论文
共 152 条
[1]   An update on antifungal targets and mechanisms of resistance in Candida albicans [J].
Akins, RA .
MEDICAL MYCOLOGY, 2005, 43 (04) :285-318
[2]   Penetration of Candida biofilms by antifungal agents [J].
Al-Fattani, MA ;
Douglas, LJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3291-3297
[3]   Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations [J].
Alexander, Barbara D. ;
Johnson, Melissa D. ;
Pfeiffer, Christopher D. ;
Jimenez-Ortigosa, Cristina ;
Catania, Jelena ;
Booker, Rachel ;
Castanheira, Mariana ;
Messer, Shawn A. ;
Perlin, David S. ;
Pfaller, Michael A. .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) :1724-1732
[4]   Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations [J].
Arendrup, Maiken Cavling ;
Perlin, David S. ;
Jensen, Rasmus Hare ;
Howard, Susan Julie ;
Goodwin, Joanne ;
Hope, William .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) :2435-2442
[5]   Gross Karyotypic and Phenotypic Alterations among Different Progenies of the Candida glabrata CBS138/ATCC2001 Reference Strain [J].
Bader, Oliver ;
Schwarz, Alexander ;
Kraneveld, Eefje A. ;
Tangwattanchuleeporn, Marut ;
Schmidt, Pia ;
Jacobsen, Mette D. ;
Gross, Uwe ;
De Groot, Piet W. J. ;
Weig, Michael .
PLOS ONE, 2012, 7 (12)
[6]   Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species [J].
Bandara, H. M. H. N. ;
Lam, O. L. T. ;
Watt, R. M. ;
Jin, L. J. ;
Samaranayake, L. P. .
JOURNAL OF MEDICAL MICROBIOLOGY, 2010, 59 (10) :1225-1234
[7]   Electrophoretic karyotyping and triazole susceptibility of Candida glabrata clinical isolates [J].
Barchiesi, F ;
Di Francesco, LF ;
Arzeni, D ;
Caselli, F ;
Gallo, D ;
Scalise, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (03) :184-187
[8]   Epidemiological trends in nosocomial candidemia in intensive care [J].
Bassetti, M ;
Righi, E ;
Costa, A ;
Fasce, R ;
Molinari, MP ;
Rosso, R ;
Pallavicini, FB ;
Viscoli, C .
BMC INFECTIOUS DISEASES, 2006, 6 (1)
[9]   Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis [J].
Bennett, JE ;
Izumikawa, K ;
Marr, KA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1773-1777
[10]   Oxidative stress response and virulence factors in Candida glabrata clinical isolates [J].
Berila, N. ;
Hyrossova, P. ;
Subik, J. .
FOLIA MICROBIOLOGICA, 2011, 56 (02) :116-121